Printer Friendly

CANTAB PHARMACEUTICALS AND CANCER RESEARCH CAMPAIGN TECHNOLOGY SIGN NEW COLLABORATIVE AGREEMENT

 CAMBRIDGE, U.K., July 19 /PRNewswire/ -- Cantab Pharmaceuticals plc (NASDAQ: CNTBY) and Cancer Research Campaign Technology Limited (CRC Technology) today announced the signing of an agreement to collaborate on the development of a novel immunotherapeutic product designed to treat genital warts and prevent their recurrence.
 The agreement gives Cantab an option to acquire exclusive worldwide rights to a family of patent applications that cover inventions made by researchers at the Beatson Institute of Cancer Research, Glasgow, and the University of Glasgow, U.K. The inventions relate to the potential for using papilloma virus proteins to treat anogenital warts, cervical cancer and laryngeal cancer.
 "Current methods for treatment of genital warts are often ineffective in preventing recurrence of disease and can cause considerable patient discomfort," said Paul Haycock, M.D., president and chief executive officer of Cantab. "We believe that our immunotherapeutic approach, under development in collaboration with the Beatson Institute and CRC Technology, will offer a more effective and acceptable approach to the management of patients suffering from this disease."
 Sue Foden, managing director of CRC Technology commented, "The original aim of this research was to establish whether it is possible to develop a vaccine which would cure or prevent papilloma virus infections in cattle. Because of the similarities of the bovine and human papilloma viruses, it is likely that what we have learnt about bovine papilloma virus infections may be readily applicable to the human situation. I am delighted that CRC Technology have been able to conclude this agreement with Cantab. The company's experience in the human papilloma virus vaccine field, together with its ability to move development quickly into clinical trials, make Cantab an ideal partner."
 Since the formation of Cantab in 1989, the company's scientists have developed expertise in the engineering of human papilloma viruses in the design of Therapeutic Antigen products to treat HPV-associated disease. Cantab's first Therapeutic Antigen product under development, TA-HPV, is a recombinant vaccinia-HPV virus for the treatment of cervical cancer. A physician-initiated clinical trial of TA-HPV in patients with cervical cancer is due to commence in 1993.
 Cantab's new program focuses on research into an engineered HPV- protein based product, TA-GW, which is designed to be administered in combination with an adjuvant immunostimulant to patients suffering from multiple or persistent genital warts. Cantab aims to use TA-GW immunotherapy to accelerate regression of existing warts and prevent or delay recurrence of disease.
 Genital warts are benign but often persistent tumors to the anogenital regions that are experienced by both men and women. The incidence of new cases of genital warts is estimated to be in excess of 1,000,000 per annum in the United States and Europe. Cantab estimates that between 20 percent and 50 percent of patients have recurrent episodes of the disease and up to 10 percent have persistent recurrent disease that is unresponsive to current therapy. Existing methods of disease treatment are often ineffective in preventing recurrence and often cause considerable patient discomfort.
 Cantab's scientists, in conjunction with a team of international collaborators in HPV research, and scientists at the Beatson Institute are collaborating on the design and development of the TA-GW drug. If initial studies are successful Cantab plans to take a license to CRC Technology's patent applications in this area.
 -0- 7/19/93
 /NOTES TO THE EDITOR: Cantab is engaged in the research and development of biopharmaceuticals that use the highly selective properties of the immune system to treat disease. The company has research and development programs in two principal areas: Leucocyte Modulators, which regulate or block immune system function, and Therapeutic Antigens, which activate specific immune responses. Cantab's initial therapeutic focus includes programs in the prevention of organ transplant rejection, the treatment of cervical cancer, the prevention of recurrence of genital herpes and research into the management of Crohn's disease.
 CRC Technology is a company wholly owned by the Cancer Research Campaign (CRC) established to realize the commercial potential of inventions and discoveries arising from CRC-funded research. The company aims to ensure that these advances in cancer research are developed to the maximum benefit of cancer patients and that through commercial exploitation a revenue stream is returned to the campaign and to the research institutions in which CRC research is carried out. CRC Technology had developed worldwide contacts with the biotechnology and pharmaceutical industries to give discoveries arising from CRC-funded research the best chance of success./
 /CONTACT: In the U.K., Paul Haycock, M.D., president and CEO of Cantab, 011-44-223-423413, or Andrew Waterworth of Ludgate Communications, 011-44-71-253-2252, for Cantab; Susan Foden, M.A., D.Phil., managing director of CRC Technology, 011-44-71-224-0124, or Mary d'Arcy Doherty, Ph.D., company secretary of CRC Technology, 011-44-71-224-0124, or Susan Osborne, head of communications of Cancer Research Campaign, 011-44-71-224-1333; or in the U.S., Anthony J. Russo, Ph.D., of Noonan/Russo Communications, 212-979-9180 for Cantab/
 (CNTBY)


CO: Cantab Pharmaceuticals plc; Cancer Research Campaign Technology
 Limited ST: IN: MTC SU:


MP-LG -- NY016 -- 2950 07/19/93 10:00 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jul 19, 1993
Words:830
Previous Article:CYBEROPTICS CORPORATION REPORTS RECORD PERFORMANCE
Next Article:/REPEATING FOR POINTS/
Topics:


Related Articles
CANTAB PHARMACEUTICALS ANNOUNCES SUCCESSFUL INITIAL PUBLIC OFFERING FIRST U.K. BIOTECH COMPANY TO LIST IPO EXCLUSIVELY IN U.S. ON NASDAQ
PHYTON CATALYTIC AND BRISTOL-MYERS SQUIBB EXPAND ON PRODUCTION OF PACLITAXEL (TAXOL(R)) FROM PLANT CELL CULTURES
CANTAB PHARMACEUTICALS REPORTS SECOND QUARTER RESULTS
ONCOGENE SCIENCE AND HOECHST MARION ROUSSEL ANNOUNCE RENEWAL OF THEIR COLLABORATIVE RESEARCH AND DEVELOPMENT PROGRAM
Quark Biotech Signs Collaborative Research Agreement with Shionogi.
QUARK SIGNS RESEARCH PACT WITH SHIONOGI.
NeoGenesis Pharmaceuticals Announces Drug Discovery Collaboration with Amgen; Amgen and NeoGenesis to pursue small molecule drugs for certain human...
Morphotek Announces Research and Development Agreement With the National Cancer Institute For the Development of Antibodies For the Treatment of...

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters